<DOC>
	<DOCNO>NCT01592370</DOCNO>
	<brief_summary>The purpose study determine side effect treatment Nivolumab combination patient relapsed/ refractory lymphoma multiple myeloma .</brief_summary>
	<brief_title>An Investigational Immuno-Therapy Study Determine Safety Effectiveness Nivolumab Daratumumab , With Without Pomalidomide Dexamethasone , Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Relapsed Unresponsive prior treatment multiple myeloma â‰¥2 course therapy , include least 2 consecutive cycle immunomodulatory agent ( IMiD ) proteasome inhibitor ( PI ) alone combination More 12 week posttransplant blood form stem cell ( autologous transplant ) Have detectable disease measure specific protein blood and/or urine Must consent bone marrow aspirate biopsy . Solitary bone extramedullary plasmacytoma evidence plasma cell dyscrasia , monoclonal gammopathy undetermined significance ( MGUS ) , smolder multiple myeloma ( SMM ) , amyloidosis , Waldenstrom 's macroglobulinemia , POEMS syndrome active plasma cell leukemia No prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , anti CTLA 4 , antiCD38 antibody , pomalidomide , allogeneic stem cell transplantation Seropositive human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen Hepatitis C antibody positive ( except HCVRNA negative ) , history active chronic hepatitis B C. History central nervous system involvement symptom suggestive central nervous system involvement multiple myeloma Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>